Welcome to our dedicated page for Syndax Pharmaceuticals SEC filings (Ticker: SNDX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Syndax Pharmaceuticals filings document regulatory disclosures for a commercial-stage cancer-therapy company. Recent Form 8-K reports furnish quarterly and annual financial results, preliminary financial information, product-revenue updates for Revuforj and Niktimvo, business presentations and material product events, including the FDA approval of Revuforj for relapsed or refractory acute myeloid leukemia with a susceptible NPM1 mutation.
The company’s proxy materials cover board elections, executive compensation, equity-award valuation and shareholder voting matters. Other material-event filings address governance changes, including director departures, and Regulation FD disclosures tied to investor presentations and operating updates.
SNDX has a Form 144 notice covering a proposed sale of 2,082 shares of its common stock through Fidelity Brokerage Services LLC on NASDAQ, with an aggregate market value of 42,931.05.
The shares were acquired on 02/05/2026 via restricted stock vesting from the issuer as compensation, with payment also dated 02/05/2026. The filing notes that 86,914,838 shares of common stock are outstanding and includes the standard representation that the seller is not aware of undisclosed material adverse information about the issuer.
The Vanguard Group filed an amended Schedule 13G reporting its beneficial ownership of Syndax Pharmaceuticals common stock as of 12/31/2025. Vanguard reports beneficial ownership of 6,230,334 shares, representing 7.16% of the outstanding common stock. It has no sole voting or dispositive power, with 702,989 shares subject to shared voting power and 6,230,334 shares subject to shared dispositive power. The filing states the securities are held in the ordinary course of business and not for the purpose of changing or influencing control of Syndax. Vanguard notes that its clients have rights to dividends and sale proceeds, with no single client holding more than 5% of the class.
Syndax Pharmaceuticals reported preliminary unaudited 2025 figures alongside a presentation at the 44th Annual J.P. Morgan Healthcare Conference. The company estimates U.S. net product revenue for Revuforj® (revumenib) at approximately $44 million for the fourth quarter and $125 million for the full year ended December 31, 2025. Niktimvo™ (axatilimab-csfr) generated an estimated $56 million in U.S. net product revenue for the quarter and $152 million for the full year, with Syndax to report its share of net commercial profit when it releases full-year 2025 results. The company also disclosed preliminary total cash, cash equivalents and marketable securities of about $394 million as of December 31, 2025. All figures are unaudited and subject to change as the year-end audit is completed.
Syndax Pharmaceuticals (SNDX) reported Q3 2025 results. Total revenue reached $45.9 million, driven by $32.0 million in Revuforj product sales and $13.9 million in Niktimvo collaboration revenue. The company posted a net loss of $60.7 million (basic and diluted EPS $(0.70)), reflecting continued investment in commercialization and development.
Operating expenses were $103.3 million, including $56.3 million in R&D and $44.9 million in SG&A. Cash, cash equivalents, and short- and long‑term investments totaled $456.1 million at quarter end, with inventory of $25.0 million. A royalty interest financing liability related to Niktimvo stood at $343.9 million (net).
Year‑to‑date through September 30, revenue was $103.6 million and net loss $217.4 million. Subsequent to quarter end, the FDA approved Revuforj on October 24, 2025 for R/R AML with an NPM1 mutation, and Revuforj was added to the NCCN Guidelines for AML on September 18, 2025.
Syndax Pharmaceuticals, Inc. filed a current report announcing that it released its financial results for the quarter and six months ended September 30, 2025. On November 3, 2025, the company issued a press release and a corporate presentation describing these results, which are included as Exhibits 99.1 and 99.2. The company notes that this earnings information is being furnished rather than filed, meaning it is not automatically subject to certain Exchange Act liabilities or incorporated into other SEC filings unless specifically referenced.
Syndax Pharmaceuticals (SNDX) announced FDA approval of Revuforj (revumenib) for the treatment of relapsed or refractory acute myeloid leukemia with a susceptible NPM1 mutation in adult and pediatric patients one year and older who have no satisfactory alternative treatment options. The company disclosed the news via a press release and held a conference call on October 24, 2025.
The filing notes forward-looking statements regarding plans to make Revuforj commercially available for this indication. A copy of the press release is furnished as Exhibit 99.1.
Michael A. Metzger, the Chief Executive Officer and a director of Syndax Pharmaceuticals, Inc. (SNDX), reported option exercise and an immediate sale on 09/08/2025. He exercised 157,307 options at an exercise price of $10.90 to acquire 157,307 shares and then sold the same 157,307 shares under a Rule 10b5-1 plan at prices ranging from $16.21 to $17.06. The filings show beneficial ownership figures of 455,968 shares after the exercise and 298,661 shares after the sale. The report states Metzger has 1,319,634 vested options immediately exercisable and 651,241 unvested options remaining. The option exercised was fully vested.
Syndax Pharmaceuticals (SNDX) reported a Notice of Proposed Sale on Form 144 indicating an intended sale of 157,307 common shares through Morgan Stanley Smith Barney (NASDAQ) with an aggregate market value of $2,680,511.28, and an approximate sale date of 09/08/2025. The shares were acquired on 09/08/2025 by exercise of stock options from the issuer, with payment in cash. The filing also discloses a prior sale by Michael Metzger of 7,534 shares on 07/16/2025 for $69,953.19. The filer certifies no undisclosed material adverse information.
Syndax Pharmaceuticals Inc director Dennis Podlesak exercised stock options for 57,600 shares of common stock at a 7.2000 per-share strike and sold 57,600 shares between August 14 and 18, 2025 pursuant to a Rule 10b5-1 plan. After these trades he directly holds 191,763 shares of common stock and 135,000 options that are vested and immediately exercisable, with no unvested options remaining.
Point72 entities and Steven A. Cohen report a 5.0% stake in Syndax Pharmaceuticals (SNDX). As of the close of business on August 15, 2025, Point72 Asset Management, L.P., Point72 Capital Advisors, Inc. and Steven A. Cohen each report beneficial ownership of 4,327,952 shares of Syndax common stock, representing 5.0% of the class. The filing shows no sole voting or dispositive power and reports shared voting and shared dispositive power of 4,327,952 shares. The statement is filed jointly pursuant to a Joint Filing Agreement (Exhibit 99.1). The issuer's principal executive office is listed at 730 Third Avenue, 9th Floor, New York, NY 10017.